The increasing popularity and therapeutic potential of conjugated monoclonal antibodies – especially the antibody-drug conjugate market – is expected to drive the conjugated monoclonal antibodies market over the forecast period. Antibody-drug conjugates (ADCs) are a class of therapeutics consisting of monoclonal antibodies (MAbs) clubbed with highly potent cytotoxic drugs through a linker, to kill the antigen-expressing tumor cells, predominantly used in the treatment of cancer. The U.S. Food and Drug Administration approved only five antibody-drug conjugates drugs from 2000 to 2018, and in 2019, it approved three antibody-drug conjugates drugs indicating that the increased number of approvals is directly proportional to the use of conjugated monoclonal antibodies, mainly in the field of cancer, which in turn aids in the growth of the market.
The global conjugated monoclonal antibodies market is expected to decline from $8.35 billion in 2019 to $8.15 billion in 2020 at a compound annual growth rate (CAGR) of -2.36%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The global conjugated monoclonal antibodies market is then expected to recover and reach $10.41 billion in 2023 at a CAGR of 8.49%.
The conjugated monoclonal antibodies market consists of the sales of conjugated monoclonal antibodies. Conjugated monoclonal antibodies are monoclonal antibodies (mAbs) associated with a chemotherapy drug or a radioactive particle. These are used in the treatment of cancer as they deliver the toxic substance directly to the tumor cells by reducing damage to the normal cells in other parts of the body.
Companies operating in the conjugated monoclonal antibodies market are focusing on strategic collaborations and partnerships. For instance, in October 2019, NovoCodex, a subsidiary of Zhejiang Medicine Co Ltd, collaborated for the second time with Ambrx Inc, a USA-based company engaged in developing protein therapeutics, to develop and commercialize Ambrx’s internally developed site-specific antibody-drug conjugate, ARX305, used for the treatment of CD70 positive cancers. Following the trend, in June 2020, Monopar Therapeutics, a US-based biopharmaceutical company, and NorthStar Medical Radioisotopes entered into a collaboration to couple Monopar’s MNPR-101, a humanized urokinase plasminogen activator receptor (uPAR) targeted monoclonal antibody in pre-IND stage, to a therapeutic radioisotope of NorthStar to create a highly selective agent, which has the potential to kill aberrantly activated cytokine-producing immune cells.
The global conjugated monoclonal antibodies market is segmented by drugs into adcetris and kadcyla. By technology, the market is segmented into cleavable linker and non-cleavable linker. By application, it is segmented into blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumour, and others.
Here Is A List Of Similar Reports By The Business Research Company:
Antibody Drug Conjugates Global Market Report 2020-30: Covid 19 Growth And Change
Monoclonal Antibodies (MAbS) Global Market Report 2020-30: Covid 19 Impact And Recovery
Biosimilar Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth And Change
Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.
Company Name: The Business Research Company
Contact Person: Oliver Guirdham
Email: Send Email
Phone: +44 20 7193 0708
State: Greater London
Country: United Kingdom